AOP Orphan team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe.
In the field of rare diseases the AOP Orphan team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.
